Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 39M | 0.5% |
| Gross Profit | 26M | 68.3% |
| Cost of Revenue | 12M | 46.3% |
| Operating expense | 48M | 8.1% |
| Net Income | -29M | 1.2% |
| EBITDA | -25M | 173.5% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 296M | 35.7% |
| Total Liabilities | 354M | 28.1% |
| Shares Outstanding | 9.8M | 84.8% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -43M | 13.4% |
| Cash from financing | 27M | 23.7% |
EPS
Financial Highlights for Bluebird bio in Q1 '25
Bluebird bio reported a revenue of 39M, which is a 0.5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 26M, marking a 68.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 12M, a -46.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 48M, showing a -8.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -29M, showing a -1.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -25M, showing a -173.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Bluebird bio faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. A decline in EBITDA signals potential operational challenges or increased costs.
